In this week’s newsletter

✅ What we know about Open AI’s new model. ✅ A new longevity PAC. ✅ DeepMind is building a virtual cell - and Hassabis is very interested in longevity. ✅ ”Little people trying to grow inside your liver.” ✅ My ambulance to the future. 

🤙🏼 Want to connect? Add me on LinkedIn. 🙏🏼 Not subscribed to the LEVITY podcast on Youtube yet? Do it here. 🎧 More of a listener? The LEVITY podcast is also available on Spotify, Apple Podcasts and other places.

Open AI gets the headlines but I want to Shift your attention to another startup using AI to tackle aging

I've often said that the biggest breakthrough in longevity science this decade isn't a specific drug or genetic discovery - it's artificial intelligence. Aging is biology, and AI is rapidly becoming the ultimate decoder of life's language.

We've already seen AI-driven biology lead to a Nobel Prize, thanks to Alphafold's protein-structure predictions, and countless other initiatives are underway across research labs and biotech companies, each contributing a piece to the puzzle.

Need AI-developed drugs or predictive modeling for clinical trial success? Insilico has that covered. Want to simulate 500 million years of evolution? That’s the mission of Evolutionary Scale. Looking for a large language model designed to create better gene-editing tools? Enter Profluent.

Meanwhile, Nvidia is making a major push into biology with its molecular design framework, and CEO Jensen Huang has declared: "For the very first time in human history, biology has the opportunity to be engineering, not science."

It was only a matter of time before someone applied this to longevity. But when that someone is OpenAI - the most influential AI company in the world - it carries a weight that few others can match. Their involvement means mainstream attention, and longevity science could certainly use more of that.

That said, with the limited information available so far, it’s hard to gauge just how groundbreaking OpenAI’s efforts in this space truly are. It very well might be, but based on what’s been shared, I can’t say I’m particularly blown away - yet.

In fact, I’m (so far) more impressed by what Daniel Ives and his company, Shift Biosciences, are working on - something Daniel shared with me last fall, which I covered here.

And I mention Shift not just because they’re also at the intersection of AI and longevity, but because there’s a deeper connection between their work and the OpenAI news.

Some context might be in order.

Subscribe to LEVITY Premium to read the rest.